Panel 1: Capital Markets and Investments Panel

Li Shanquan: Managing Director/ Senior Portfolio Manager of Oppenheimer Funds

Mr. Li Graduated from Remin University Of China in 1982. After his graduation, he was recruited by the Development Research Center of the State Council. In 1986, he was selected as Humphrey Fellow and was invited to the United States by Winston Lord, Ambassador of the US in Beijing. He earned his Master degree in International Finance at Brandeis University in 1989. He started asset management practice as an analyst at Acadian Asset Management in 1990. In 1991, he joined Brown Brothers Harriman as a Senior Analyst in the Investment Management Policy Group. In 1995, he started at Oppenheimer Funds in the Global Equity Group as a portfolio manager.

Jay Guo, Ph.D.:, Global Head of Fixed-income Quantitative Methodology Group and Structured Securities Group, Interactive Data

Jay is Global Head of Fixed-income Quantitative Methodology Group and Structured Securities Group at Interactive Data (IDCo). He is also in charge of China region business initiative and operation. He currently serves as an adjunct professor of the Zicklin School of Business at the CUNY. Prior to joining IDCo, he was with a hedge fund – Seer Capital and responsible for trading strategies and analytics for MBS and ABS. He was a Director and trader at Credit Suisse Global Prop Trading Division. His main focus was on mortgage credit products. Prior to assuming that role, he was a Direct at Credit Suisse Structured Products Strategy & Research Group, which has been consistently ranked as the All-America Research Team by Institutional Investors in 2004, 2005, 2006, and 2007. Jay joined Credit Suisse from Fannie Mae, where he was an economist in Credit Policy and Finance Division. Jay has published a dozen research articles in leading finance and economics journals, such as Oxford Bulletin of Economics and Statistics, Journal of Future Market, Journal of Structured Finance, et al. His views and research on mortgage and real estate markets have been quoted by The Wall Street Journal, Chicago Tribune, Market Watch, The New York Times, Business Week, et al. Jay holds a Ph.D. in Economics from Indiana University, Master degrees in Economics and Statistics, and a B.S. in Mathematics from Beijing Normal University (BNU). He is a member of the Board of Directors of the not-for-profits BNU Education Foundation, and Global Chinese Real Estate Congress.

Yong Li: Managing Director, Midway Group

Dr. Yong Li is currently Managing Director in charge of risk management at the Midway Group, a top ranked fixed income hedge fund located in downtown New York. Dr. Li joined the Midway Group in February 2003 with more than ten years of expertise in financial modeling, risk management, and quantitative analysis.

Prior to joining the Midway Group, Dr. Li was a senior risk manager at the Lehman Brothers Inc. and ran a risk management group for five years with key responsibilities for the global credit businesses. Before that, he was a risk manager for three years at the Credit Lyonnais Americas covering market risk for the fixed income and equities businesses.

Dr. Li spent two years as a quantitative analysis at Sanwa Financial Products, the derivative subsidiary of Sanwa Bank, building interest rate and currency derivative pricing models and structuring tools. He also worked over one year at the AT&T Bell Labs doing data analysis and statistical modeling.

Dr. Li served as Director of the Global Association of Risk Professionals for three years from 1997 to 2000 and was responsible for the Financial Risk Manager’s Certification Program for the first three years from 1997 to 2000.

Dr. Li holds a Ph.D. with a research focus in Operations Research and M.S. in Applied Mathematics, both from the Pennsylvania State University, University Park, PA, USA.

Robert Fallon: Moderator, Professor, Finance and Economics, Columbia Business School.

Professor Fallon returned to Columbia in 2008 after completing a successful turnaround of Korea Exchange Bank, a publicly listed $80 billion institution that is Korea’s leading international bank. After taking over as President and CEO, he successfully led a wholesale reorganization and restructuring that restored the bank’s capital strength and profitability, achieving record net income in 2004. He was also the first foreigner to chair a public company in Korea. Previously Fallon was head of global financial services with JP Morgan Chase and prior to that, resident for many years in Tokyo as Asia-Pacific division head where he was responsible for Chase’s activities in thirteen different countries across Asia. Professor Fallon’s research interests include international banking and Asian financial and economic affairs. He has lived in Asia for thirty-one years and enjoys myriad contacts across a wide spectrum of government, corporate and financial institutions in the region. He travels widely and speaks often on regional economic and business affairs. He started his banking career with Citibank in Hong Kong in 1975 and later worked in investment banking and management positions in Tokyo. Subsequently he assumed Asia regional responsibility with Drexel Burnham Lambert and Bankers Trust Company before joining Chase in 1992. Mr. Fallon holds a BA from Ohio University and an MBA from Harvard Business School. Following his undergraduate studies, he served in the U.S. Peace Corps, including three years as a volunteer mathematics teacher at Chanel College in Western Samoa. Mr. Fallon is currently a Director of the Japan Society, Director of the Korea Society, Trustee of the Ohio University Foundation, Director of the Council on International Educational Exchange and a Professional Fellow of the Center on Japanese Economy and Business of Columbia University. He serves on the Advisory Board of the Korea Economic Institute and the Asian Advisory Boards of Deutsche Bank AG and Euromoney PLC and is a member of the Council on Foreign Relations.

Panel 2: Healthcare

Dr. Joanne Jiang: Co-Founder and VP, Fountain Medical Development

Dr. Joanne Jiang, VP, Business Development and International Project Management, Fountain Medical Development

Dr Jiang has been working in the pharmaceutical industry for 14 years. She started her career in preclinical pharmacology area at Bayer pharmaceutical and Eli Lilly, working as research scientist, lab head and project leader. She further developed expertise in drug development and project management through her tenure as global project manager since year 2000. From year 2000 to 2007, at Aventis and then Daiichi Sankyo, she managed drug development and life cycle management projects, encompassing preclinical to phase IV activities. She especially focused on clinical trial planning and management, integrating marketing plans and regulatory strategy that enables optimal trial design. Dr. Jiang also has working knowledge of building and managing high performing project teams that deliver break-through results. Starting in 2007, Dr Jiang co-founded Fountain Medical Development, a contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services for multinational clients conducting clinical research in Asia. As a full clinical service provider, Fountain Medical Development has recently become the leading CRO in China in delivering quality results for global clinical studies.

Dr. Jiang holds a PhD in pharmacology and toxicology from Indiana University, and an MBA from University of Michigan Dearborn.

Dr. Jiang was an Executive Council for Sino-American Pharmaceutical Association. She is also a member of Project Management institute and Drug information association.

Dr. Roger Xie: , , Head of Global Development and Chair of Scientific Advisory Board, China PharmaHub Corp.

Roger Xie, Ph.D., is currently EVP, Head of Global Development and Chair of Scientific Advisory Board at China PharmaHub Corp.

China PharmaHub Corp. (the “Company" or "PharmaHub") is a global pharmaceutical HUB that specializes in the identification, licensing, development and commercialization of pharmaceutical, healthcare products and technologies that could make a significant difference to patients and society worldwide. PharmaHub’s corporate goal is to create maximum value from existing intellectual properties and technologies of its global partners by utilizing its broad-base knowledge, understanding and resource allocation ability in the pharmaceutical & healthcare industries. Currently, PharmaHub is founding and co-founding a number of start-ups with launched drugs and certain exclusive licensing arrangements in multiple disease areas for small molecule therapeutics, biopharmaceuticals, diagnostics, medical device and delivery technologies.

Inspired by Thomas Jefferson’s famous quote of “Every generation needs a new revolution,” PharmaHub’s founders believe that the Company can revolutionize the global pharmaceutical industry scientifically and commercially and converting Pharma’s problems into opportunities and benefits to our patients, US/China health care system and worldwide medical community.

Dr. Xie is an international expert on emerging opportunities for drug discovery and development and has deep ties and roots in the biotech and scientific business community in Cambridge, Massachusetts as well as China. Dr. Xie is a seasoned executive providing strategic, technical, marketing, financial and operations experience. He is an experienced Biotechnology and Pharmaceuticals Executive having led drug discovery organizations and held leadership positions in privately-held and public corporations such as CEO of Beijing PharmaScience, Associate Director of Chemistry Operations of Sirtris Pharma (a GSK company), Principal Scientist and Program Leader of Daiamed, Sr. Scientist of UCB Research, Inc. and Sr. Scientist of Sepracor, Inc.

Michael Balaban: Founder & Principal, Balaban Associates

Mr. Balaban has been actively involved in international finance for more than 25 years. He spent 15 years in business development & client relationship management spanning the fixed income, equity and corporate finance sectors, followed by 10 years in cross-border consulting and executive management focused on financial information & media Mr. Balaban’s global perspective includes deep knowledge of the business landscape in Asia and an extensive network of global connections.

Currently, Mr. Balaban is founder & Principal at Balaban Associates LLC, offering cross-border strategic advice to corporate and financial services clients whose operations or aspirations include an Asia component.

From 2004 until December 2008, Mr. Balaban was Managing Director (Global Integration) and a member of the Executive Committee of Xinhua Finance Ltd., a Tokyo-listed provider of global financial information with headquarters in Shanghai and operations in the US & Europe.

While running his own US-Asia cross-border strategic & financial advisory business from 1999-2004, Mr. Balaban and his team drafted Xinhua Finance’s business and strategic plans, raised private equity for it, introduced it to strategic partners and identified attractive acquisition targets. Mr. Balaban performed similar services for a host of other China-based and western corporate clients during that period.

From 1996 through 1999, Mr. Balaban served as Deputy Head of Smith Barney’s Asia Corporate Finance Group and, after that firm’s mergers with Salomon Brothers and Citibank, head of Citigroup’s Equity Capital Markets Group in Japan.

From 1980 through 1995, Mr. Balaban worked in fixed income & corporate finance at Lehman Brothers, focusing on business development with the firm's overseas clients. In 1987, Mr. Balaban was named to head the firm’s Japan Desk.

Mr. Balaban graduated from Brown University with honors. He received an A.B. degree with dual majors in international relations & political science. He also earned an M.A. degree in international relations from the Fletcher School at Tufts University (in cooperation with Harvard University). He has spoken at many conferences, written published articles, and serves on the board of several charitable organizations.

Panel 3: Private Equity and Venture Capital Panel (PEVC)

Alexi Ripley: Principal at Bain Capital.

Mr. Ripley joined Bain Capital in 2005. Previously, he worked at Madison Dearborn Partners and was an investment banker at Donaldson, Lufkin & Jenrette. He has recently spent one year in Bain Capital Hong Kong office working on various investments in Mainland China. Mr. Ripley received an MBA from Harvard Business School and graduated magna cum laude in History from Brown University, where he was elected to Phi Beta Kappa.

Jonathan Pan: , Partner and Head of King & Wood New York Office.

Mr. Pan joined King & Wood in 2006. Prior to this, he worked as an associate with Haythe & Curley (now Torys) in New York and as a senior associate at the Hong Kong office of Allen & Overy respectively. Mr. Pan has also worked at the Ministry of Foreign Affairs of the People’s Republic China. King & Wood is China’s leading law firm with its 16 offices located throughout China, U.S. and Japan. Mr. Jonathan Pan specializes in foreign direct investment, private equity investment, M&A and project finance.

Hao Wu: Partner at Sino-Century China Private Equity Partners

Dr. Wu was born in China and educated in both China and the U.S. Dr. Wu received his B.S. in Physics from Fudan University in Shanghai and his Ph.D. degree in Electrical Engineering and MBA in Finance both from University of Southern California in Los Angeles. He also attended Executive Education Programs at Harvard Business School. Before co-founding Pinetree Capital and re-launching Sino-Century along with Dr. Chang to invest high-growth private companies in China in 2005, Dr. Wu worked at a number of financial service firms, including AIG Global Investment where he advised AIG companies in Asia and in Europe. He is a Chartered Financial Analyst (CFA) and is a member of Institute of Electrical and Electronics Engineers (IEEE).

Overview    |    Panels    |    Speakers    |    Agenda    |    Registration    |    Sponsors